Medicare rules, CMS guidance, reimbursement, and benefit changes affecting patients and providers.
Minnesota’s Medicaid funding deferral does not automatically end coverage. The closer short-term risk is provider payment strain, tighter oversight, and access friction.
CMS began enforcing updated hospital price transparency requirements on April 1, 2026. Here’s what patients can actually compare before planned care, what changed in hospital price files, and why the posted number is still not a final bill.
Medicare changed how it pays for many skin substitute products used in diabetic foot ulcers in 2026, but it did not broadly stop covering care. Here’s what the change may mean for access, treatment conversations, and when to seek help.
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
Osteoporosis is often treated like a women’s issue, but men can develop it too and may be diagnosed only after a serious fracture. Here is who should ask about a DXA bone density scan, how national policy differs from specialty guidance, and what Medicare may or may not cover.
CMS has started a limited Original Medicare pilot in six states that uses technology vendors and clinician review for a narrow set of services. Here’s what WISeR does, what has not changed, how reviews and appeals work, and why some experts worry about delays.
As of April 2, 2026, nothing changes at the pharmacy yet for Medicare patients taking Xeljanz, Orencia, Cosentyx, or Cimzia. What changed is that Medicare has selected these drugs for its third negotiation cycle, manufacturers are participating, and any negotiated prices would not begin until January 1, 2028.
A November 6, 2025 study found that hearing loss was common among Hispanic Medicare beneficiaries age 65 and older, but hearing aid use was much lower. Here is what the study found, what Original Medicare does and does not cover, where OTC hearing aids may fit, and when it is time to get tested.
CMS has announced first-year awards in all 50 states under a five-year rural health program. The funding could help states recruit, train, and keep more clinicians, but federal workforce data show rural primary care shortages remain deep and patient-facing relief is likely to take time.
Federal enforcement of updated hospital price transparency requirements begins April 1, 2026. That may make some hospital price listings more useful for planned care, but posted prices still are not the same as your final out-of-pocket bill.
Certain Medicare Advantage, Medicaid, CHIP, and HealthCare.gov marketplace plans now have to post prior authorization data from 2025. Here’s what patients can check, what the numbers mean, and what the reports still leave out.
CMS is asking states to break out more Medicaid and CHIP quality results by race and ethnicity, sex, and geography in 2026. That could make gaps in child, pregnancy, and behavioral health care easier to see, but better reporting alone will not fix unequal care.
CMS now requires hospitals to report clearer dollar-based pricing fields in their machine-readable files for 2026. That could make gathered pricing data easier to analyze, but it still does not give most patients an exact out-of-pocket quote.
Medicare covers some diabetes-related foot care in 2026, but not unlimited routine foot care for everyone. Here’s who qualifies for Part B foot exams and treatment every 6 months, what therapeutic shoes may be covered, what you may pay, and which symptoms should be checked sooner.
As of March 27, 2026, the CDC still clearly recommends 2 doses of the 2025–2026 COVID-19 vaccine for adults 65 and older. Here is how the timing works, why age still matters, what Medicare covers, and what remains uncertain.
A 2026 Medicare policy update gives eligible beneficiaries more ways to join the Medicare Diabetes Prevention Program, including live online and on-demand sessions through December 31, 2029. Here’s who qualifies, what the program includes, what Medicare pays, and why the access change matters for older adults with prediabetes.
Medicare has extended many telehealth flexibilities through 2026. Here’s what that means for receiving care at home, what’s covered, what you pay, and what could change next.
A new March 2026 report from MedPAC examines how Medicare payment policy is affecting rural hospital finances and the rise of Rural Emergency Hospitals. Here’s what it means for emergency access, maternity care, travel distances, and insurance coverage in rural communities.
CDC’s 2025–2026 recommendations for influenza, COVID-19, and RSV vaccination clarify who should be vaccinated, when doses should be given, and how coverage works under Medicare and private insurance. Here’s what patients and physicians need to know this season.
New FDA-approved obesity medications have changed treatment options—but Medicare’s long-standing drug coverage rules still shape who can access them. Here’s what adults and families should understand in 2026 about eligibility, costs, and policy limits.
FDA-approved anti-amyloid drugs such as lecanemab are now in real-world use for early Alzheimer’s disease. Here’s who qualifies, what the main clinical trial showed, what ARIA risks mean, and how Medicare coverage works in the United States.
FDA traditional approval of lecanemab for early Alzheimer’s disease offers modest slowing of decline for some patients—but requires careful screening, MRI monitoring, and meeting Medicare coverage rules. Here’s what families should understand in 2026.
End of content
End of content